Eleva Capital’s NewAmsterdam Pharma NAMS Stock Holding History

Eleva Capital’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-25,721	Closed	-$823K	–	37
2026 Q2	$823K	Hold	25,721	–	–	0.24%	14
2026 Q1	$823K	Buy	+25,721	New	+$838K	0.24%	14

Eleva Capital's NAMS Position: Q3 2026 in Review

Eleva Capital sold out of NewAmsterdam Pharma (NAMS) in Q3 2026, closing a stake of 25,721 shares — an estimated $823K sold.

Eleva Capital first reported a position in NAMS in Q1 2026 and held it in 2 quarters. The position peaked at $823K in Q2 2026. 0 funds tracked by Wall St. Rank hold NAMS as of Q3 2026.

Eleva Capital reported no remaining NewAmsterdam Pharma position as of Q3 2026 after selling out during the quarter.
Eleva Capital sold 25,721 NewAmsterdam Pharma shares in Q3 2026, an estimated $823K.
Eleva Capital first reported a position in NewAmsterdam Pharma in Q1 2026 and held it in 2 quarters.
Eleva Capital's NewAmsterdam Pharma position peaked at $823K in Q2 2026.
0 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q3 2026.

Based on Eleva Capital's 13F filing for Q3 2026, filed 6 Oct 2026.